Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

92.88CHF
20 Mar 2019
Change (% chg)

CHF-0.24 (-0.26%)
Prev Close
CHF93.12
Open
CHF92.52
Day's High
CHF93.30
Day's Low
CHF92.52
Volume
1,896,838
Avg. Vol
5,111,667
52-wk High
CHF93.96
52-wk Low
CHF71.84

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  NOVN.S Industry Sector
P/E (TTM): 31.37 29.30 32.54
EPS (TTM): 2.68 -- --
ROI: 6.14 14.23 13.82
ROE: 9.19 15.46 15.25

Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

20 Mar 2019

UPDATE 1-Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

20 Mar 2019

BRIEF-Novartis' Alcon Acquires U.S. Medical Company For $285 Mln

* ACQUISITION FURTHERS ALCON'S COMMITMENT TO BRING THIS INNOVATIVE, ACCOMMODATING LENS TO CATARACT PATIENTS THROUGHOUT WORLD

18 Mar 2019

BRIEF-Novartis Late-Breaking Data Further Support Initiation Of Entresto In Hospital

* NOVARTIS LATE-BREAKING DATA FURTHER SUPPORT INITIATION OF ENTRESTO IN HOSPITAL AND AS FIRST-CHOICE SYSTOLIC HEART FAILURE THERAPY IN STABILIZED PATIENTS

16 Mar 2019

Novartis generics boss quits amid conjecture over business's future

ZURICH Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.

14 Mar 2019

Novartis names new CEO for Sandoz generics business

ZURICH, March 14 The chief executive of Sandoz, the generics business of Swiss drugmaker Novartis, is stepping down "for personal reasons", the company said on Thursday.

14 Mar 2019

Novartis has no plans to sell Sandoz: chairman

ZURICH Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business, Chairman Joerg Reinhardt said in a newspaper interview, saying it was keeping its options open.

05 Mar 2019

UPDATE 1-Novartis has no plans to sell Sandoz - chairman

ZURICH, March 5 Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business, Chairman Joerg Reinhardt said in a newspaper interview, saying it was keeping its options open.

05 Mar 2019

Novartis has no plans to sell Sandoz - chairman

ZURICH, March 5 Swiss drugmaker Novartis has no plans to sell all or parts of its Sandoz generics business, Chairman Joerg Reinhardt said in a newspaper interview, saying it was keeping its options open.

05 Mar 2019

BRIEF-Danone/Novartis-backed 'Health for Life Capital II' fund announces first close

* 'Health for Life Capital II', a world-leading microbiome-focused fund, announces its first close

05 Mar 2019

Earnings vs. Estimates